Novartis and Catalent enter agreement to manufacture SMA gene therapy
Catalent Biologics works with Novartis to develop and manufacture its SMA gene therapy treatment and provide manufacturing capacity, as the treatment enters the market.
Top Headlines
Global Industry News
-
FDA finds cGMP documents in Strides’ scrap yard
from in-PharmaTechnologist.com
-
Single dose epinephrine injections from Sandoz to retail at lower cost than generic EpiPens
from in-PharmaTechnologist.com
-
Marken acquires three European firms, assessing additional deals: ‘Stay tuned,’ says CEO
from Outsourcing-Pharma.com
-
Score: Data-sharing practices improve after public ranking
from Outsourcing-Pharma.com
Hot Topics
-
UK cell and gene manufacturing employment increases by 30%
Cell & Gene Therapies
-
Boehringer looks to oncology vaccines with €325m acquisition
Pipelines
-
‘Dead cells don’t cure cancer’: BioLife acquires cold-chain solutions
Cell & Gene Therapies
-
US failure to adopt biosimilars costs $7.2bn every year
Biosimilars
